Skip to main content

Table 2 Clinical criteria for definition of patients with a better response to BT

From: Bronchial thermoplasty in severe asthma: a real-world study on efficacy and gene profiling

T2-high endotype T2-low endotype
Patient ID OCS
reduction at T12 versus baseline (%)
Number of exacerbations
at T12 versus T2
ACQ
score
at T12
Patient ID OCS
reduction at T12 versus baseline (%)
Number of exacerbations at T12 versus T2 ACQ
score
at T12
1 100 1 2.0 2 50 1 2.5
3 100 0 1.5 5 80 2 2.0
4 0 2 2.4 9 100 1 1.0
6 50 1 2.6 11 100 0 2.6
7 100 0 0 13 100 1 1.6
8 100 1 0.6 14 50 0 1.4
10 50 2 1.2 15 0 2 1.0
12 100 0 1.6 18 100 1 2.0
16 75 1 1.2 19 NA 0 1.2
17 75 2 1.4 20 100 1 1.8
25 50 2 1.4 21 75 1 1.2
26 100 2 2.1 22 NA 1 1.6
27 50 3 2.5 23 50 1 1.6
  24 100 2 1.2
Total responder: 22 (81%)
  1. Patients were classified as responders when they had at least 2 of the 3 outcome measures: (1) ACQ score < 1.5 at T12; (2) < 2 asthma exacerbations at T12 versus T2; (3) OCSs reduction of at least 50% at T12 versus baseline. Patients who did not receive OCSs at baseline (NA) were classified as responders when they had one of the other outcome measures
  2. OCS oral corticosteroids, NA (not applicable) patients who did not take OCS at baseline, Colored patient boxes = responders